RMD · News · 20260807N

Macroeconomic Factors Impact

RESMED INC · 2026-08-07 · Importance 10 · Surprise 6

Third-party earnings coverage identified tariff, inflation, and hospital-spending pressures as risks entering ResMed's fiscal 2026 results. Subsequent coverage cited increased inflation as a headwind alongside the Astral sales suspension and portfolio changes. The reporting did not quantify a company-specific tariff charge or identify a new tariff policy affecting ResMed.

Key facts

• ResMed said rising inflation is a headwind affecting the company. source
• Wells Fargo adjusted its price target for ResMed from $225 to $215 on August 7, 2026. source
• RBC Capital raised its price target for ResMed to $244 from $234 while maintaining a Sector Perform rating. source